Render Target: SSR
Render Timestamp: 2024-11-14T22:45:14.889Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:58:40.718
Product last modified at: 2024-09-30T08:00:34.617Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FATP2/SLC27A2 (E8F8O) Rabbit mAb #78771

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 70
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FATP2/SLC27A2 (E8F8O) Rabbit mAb recognizes endogenous levels of total FATP2/SLC27A2 protein. This antibody does not cross-react with FATP1/SLC27A1 protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val381 of human FATP2/SLC27A2 protein.

    Background

    Fatty acid transport protein 2 (FATP2), also known as solute carrier family 27 member 2 (SLC27A2), transports long-chain fatty acids into cells at the cell membrane. FATP2/SLC27A2 also functions as a very long-chain acyl-CoA synthetase in the endoplasmic reticulum to activate very long-chain fatty acids (1). Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are pathologically activated neutrophils that accumulate in many diseases. The immunosuppressive activity of PMN-MDSCs is critical in regulating immune responses in cancer. Studies show that FATP2/SLC27A2 expression is upregulated in PMN-MDSCs. FATP2/SLC27A2 mediates the suppressive activity of PMN-MDSCs by increasing the uptake of arachidonic acid and synthesis of prostaglandin E2. In addition, deletion of FATP2/SLC27A2 is shown to abolish the suppressive activity of PMN-MDSCs (2). These results suggest that targeting FATP2/SLC27A2 may increase anti-tumor immunity (2,3).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.